Delving into the Latest Updates on Laboratoires Biocodex with Synapse

概览

排名前五的药物类型	数量

生物药	1

关联

1

项与 Laboratoires Biocodex 相关的药物

MaaT-001

靶点-

作用机制-

在研机构

Laboratoires Biocodex [+1]

原研机构

Maat Pharma SA

在研适应症

肠道疾病

非在研适应症-

最高研发阶段临床阶段不明

首次获批国家/地区-

首次获批日期-

1

项与 Laboratoires Biocodex 相关的临床试验

NCT03122665 / CompletedN/AIIT

Effectiveness of Nefopam for Thermoregulation During Surgery

Nefopam may help blunt thermoregulatory defenses, thus facilitating induction of therapeutic hypothermia

开始日期2004-08-01

申办/合作机构

The Cleveland Clinic Foundation

[+1]

100 项与 Laboratoires Biocodex 相关的临床结果

登录后查看更多信息

0 项与 Laboratoires Biocodex 相关的专利（医药）

登录后查看更多信息

12

项与 Laboratoires Biocodex 相关的文献（医药）

2014-01-01·Pharmacology4区 · 医学

Anti-Hypercholesterolemic Effect of <b><i>Saccharomyces boulardii</i></b> in the Hamster

4区 · 医学

Article

作者: Girard, Philippe ; Pansart, Yannick ; Verleye, Marc

BACKGROUND/AIMSHypercholesterolemia is a major risk factor for coronary artery disease and probiotics have been suggested as tools to manage elevated cholesterol levels.METHODSThe present study investigated the ability of the biotherapeutic agent Saccharomyces boulardii (Sb-Biocodex) to reduce the hypercholesterolemia induced by a 0.1% cholesterol-enriched diet in the hamster.RESULTSIn a first experiment, chronic oral treatment with S. boulardii at 12 × 10(10) CFU/kg (3 g/kg) twice a day was started from the beginning of the cholesterol diet and continued for 14 days ('preventive protocol'). In the second experiment, S. boulardii was given 14 days after the beginning of the cholesterol diet when hypercholesterolemia had developed and continued for an additional 14 days ('curative protocol'). In the preventive protocol, administration of the yeast significantly reduced hypercholesterolemia (14%) induced by the cholesterol-enriched diet compared to the group receiving only the cholesterol diet. In the curative protocol, S. boulardii significantly reduced hypercholesterolemia (12%) induced by the cholesterol-enriched diet, too. Moreover, the yeast significantly decreased the serum triglyceride increase by 39%.CONCLUSIONS. boulardii possesses anti-hypercholesterolemic properties in the hamster worthy of further evaluation in clinical studies.

2003-04-01·Therapeutic Drug Monitoring3区 · 医学

Effect of Route of Administration on the Pharmacokinetic Behavior of Enantiomers of Nefopam and Desmethylnefopam

3区 · 医学

Article

作者: Marie Emmanuelle Le Guern ; Christine Alquier ; René H. Levy ; Thomas F. Kalhorn ; Jyoti Chawla

Nefopam hydrochloride is a non-narcotic analgesic used parenterally and orally as a racemic mixture for the relief of postoperative pain. However, no information is presently available on the oral kinetics of (+) and (-) nefopam in humans. Also, nefopam is metabolized by N-demethylation but it is not known whether the desmethylnefopam enantiomers (DES1 and DES2) are present in plasma following intravenous (I.V.) or oral administration of parent drug. To address these issues, 24 healthy white male subjects received two treatments using a double-blind, placebo-controlled crossover design: oral administration of 20 mg nefopam hydrochloride solution or a placebo solution on a sugar cube, simultaneously with a continuous infusion of 20 mg nefopam hydrochloride or placebo infusion. A chiral assay using LC-MS was developed for the simultaneous determination of both enantiomers of the parent drug and its metabolite in plasma and urine. Following I.V. administration, the kinetics of (+) and (-) nefopam could be fitted to a bi-exponential equation but exhibited no stereoselectivity. Both enantiomers had large clearances (53.7 and 57.5 L/hr) and volumes of distribution (390 and 381 L) and half-lives around 5 hours. Following oral administration, (+) and (-) nefopam were rapidly absorbed with bioavailabilities of 44% and 42%, respectively, probably due to a first-pass effect. After I.V. administration, the enantiomers of desmethylnefopam exhibited lower concentrations and longer half-lives (20.0 h for DES1 and 25.3 h for DES2) relative to nefopam enantiomers. Following oral administration, desmethylnefopam enantiomers' plasma concentrations peaked earlier and higher than after I.V. administration (P < 0.05). Following I.V. and oral administration, desmethylnefopam enantiomers showed stereoselectivity in AUC and Cmax values. Urinary excretion of parent and metabolite enantiomers was less than 5% of dose. This study shows that desmethylnefopam enantiomers can contribute to the analgesic effect of racemic nefopam only when it is administered orally.

1999-10-01·NeuroReport4区 · 医学

Interactions of etifoxine with the chloride channel coupled to the GABAA receptor complex

4区 · 医学

Article

作者: Schlichter, Remy ; Gillardin, Jean-Marie ; Verleye, Marc

This study examined the nature of the interactions of etifoxine, an anxiolytic and anticonvulsant compound, with the GABA(A) receptor/chloride channel complex. In membrane preparations of Sprague-Dawley rat cerebral cortex, etifoxine competitively inhibited the binding of [35S]t-butylbicyclophosphoro-thionate (TBPS), a specific ligand of the GABA(A) receptor chloride channel site. In vivo studies demonstrated an anticonvulsant effect of etifoxine (50 and 75 mg/kg, i.p.) against the clonic convulsions induced by TBPS in CD1 mice. Flumazenil (10 and 40 mg/kg, i.p.), an antagonist of benzodiazepine sites at GABA(A) receptors, had no effect on the action of etifoxine. These findings suggest that etifoxine exerts its effect by interacting with the Cl- channel of GABA(A) receptors and probably by facilitating GABAergic inhibition.

100 项与 Laboratoires Biocodex 相关的药物交易

登录后查看更多信息

100 项与 Laboratoires Biocodex 相关的转化医学

登录后查看更多信息